Immune checkpoint inhibitor–associated electrolyte disorders: query of the Food and Drug Administration Adverse Event Reporting System

Immune checkpoint inhibitor (ICI)–associated adverse events, such as hyponatremia and other electrolyte abnormalities, in patients receiving ICIs have not been well characterized. 1 Manohar S. Kompotiatis P. Thongprayoon C. et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrol Dial Transplant. 2019; 34: 108-117 Crossref PubMed Scopus (110) Google Scholar , 2 Jhaveri K.D. Sakhiya V. Wanchoo R. et al. Renal effects of novel anticancer targeted therapies: a review of the Food and Drug Administration Adverse Event Reporting System. Kidney Int. 2016; 90: 706-707 Abstract Full Text Full Text PDF PubMed Scopus (26) Google Scholar , 3 Seethapathy H, Rusibamayila N, Chute DF, et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa272. Accessed March 5, 2021. Google Scholar , 4 Izzedine H, Chazal T, Wanchoo R, Jhaveri KD. Immune checkpoint inhibitor-associated hypercalcaemia [e-pub ahead of print]. Nephrol Dial Transplant. https://doi.org/10.1093/ndt/gfaa326. Accessed March 18, 2021. Google Scholar